

Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011

Part A- Details of the Acquisition

Name of the Target Company (“TC”)	Suven Pharmaceuticals Limited		
Name(s) of the acquirer and Persons Acting in Concert (“PAC”) with the acquirer	Acquirer: Berhyanda Limited PAC 1: Berhyanda Midco Limited PAC 2: Jusmiral Midco Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	0	0%	0%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
c) Voting rights (“VR”) otherwise than by equity shares	0	0%	0%
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0	0%	0%
e) Total (a+b+c+d)	0	0%	0%

<p>Details of acquisition</p> <p>a) Shares carrying voting rights acquired</p> <p>b) VRs acquired otherwise than by equity shares</p> <p>c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired</p> <p>d) Shares in the nature of encumbrance (pledge/lien non-disposal undertaking/ others)</p> <p>e) Total (a+b+c+d)</p>	<p>12,75,37,043 #</p> <p>0</p> <p>0</p> <p>2,51,94,957 &</p> <p>15,27,32,000 #&</p>	<p>50.10%#</p> <p>0%</p> <p>0%</p> <p>9.90%&</p> <p>60.00% #&</p>	<p>50.10%#</p> <p>0%</p> <p>0%</p> <p>9.90%&</p> <p>60.00% #&</p>
<p>After the acquisition, holding of acquirer along with PACs of:</p> <p>a) Shares carrying voting rights</p> <p>b) VRs otherwise than by equity shares</p> <p>c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition</p> <p>d) Shares in the nature of encumbrance (pledge/lien non- disposal undertaking/ others)</p> <p>e) Total (a+b+c+d)</p>	<p>12,75,37,043#</p> <p>0</p> <p>0</p> <p>2,51,94,957 &</p> <p>15,27,32,000 #&</p>	<p>50.10%#</p> <p>0%</p> <p>0%</p> <p>9.90%&</p> <p>60.00% #&</p>	<p>50.10%#</p> <p>0%</p> <p>0%</p> <p>9.90%&</p> <p>60.00% #&</p>
<p>Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/ encumbrance, etc.)</p>	<p>Acquisition by way of an “off-market” purchase pursuant to the SPA&.</p>		

Salient features of the securities acquired including time till redemption, ratio, at which it can be converted into equity shares, etc.	Equity shares carrying voting rights ^{&} .
Date of acquisition of shares/ date of receipt of intimation of allotment of shares /VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	29 September 2023
Equity share capital / total voting capital of the TC before the said acquisition	25,45,64,956 equity shares of the TC (as per the shareholding pattern as on 30 June 2023 as publicly disclosed by the TC)
Equity share capital/ total voting capital of the TC after the said acquisition	25,45,64,956 equity shares of the TC (as per the shareholding pattern as on 30 June 2023 as publicly disclosed by the TC)
Total diluted share/voting capital of the TC after the said acquisition	25,45,64,956 equity shares of the TC (as per the shareholding pattern as on 30 June 2023 as publicly disclosed by the TC)

[#] The Acquirer has triggered a mandatory open offer in compliance with Regulations 3(1) and 4 and other applicable regulations of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“**Takeover Regulations**”), pursuant to the execution of the SPA (as defined in [&] below) to acquire more than 25% of the equity share capital of the Target Company and control over the Target Company. In this regard, the Acquirer has initiated the process for the open offer and has issued a public announcement on 26 December 2022, published the detailed public statement on 2 January 2023 and submitted a draft letter of offer with the Securities and Exchange Board of India on 9 January 2023, in accordance with the applicable provisions of the Takeover Regulations. The Acquirer has acquired 12,75,37,043 equity shares of the Target Company pursuant to the SPA in compliance with Regulation 22(2) of the Takeover Regulations.

[&] In terms of the share purchase agreement dated 26 December 2022, as amended (“**SPA**”) entered into between Berhyanda Limited (as Acquirer) (“**Acquirer**”), Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of Jasti Family Trust) (as Seller) (“**Seller**”) and Mr. Venkateswarlu Jasti (as Seller Representative) (“**Seller Representative**”), on and from consummation of the SPA (in terms of and subject to the SPA), and for a period of 18 months thereafter, the Seller and/or the Seller Representative shall not, without the prior written consent of the Acquirer, sell or otherwise encumber any equity shares of the TC held by them in favour of any person. As on the date of making this disclosure, the Seller and Seller Representative hold 2,51,92,957 equity shares (9.90% stake) and 2,000 equity shares (0.00% stake) in the TC respectively after the sale of 12,75,37,043 equity shares (50.10% stake) to the Acquirer pursuant to the SPA. Accordingly, such 2,51,92,957 equity shares (9.90% stake) and 2,000 equity shares (0.00% stake) represent shares taken by way of encumbrance by the Acquirer under Regulation 29(4) of the Takeover Regulations. The actual acquisition pursuant to the SPA by the Acquirer is limited to only 12,75,37,043 equity shares (50.10% stake) in the TC.

Part- B***

Name of the Target Company: Suven Pharmaceuticals Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
Acquirer: Berhyanda Limited	Yes	
PAC 1: Berhyanda Midco Limited	&&	
PAC 2: Jusmiral Midco Limited	&&	

&& PAC 1 and PAC 2 do not hold any equity shares in the TC.

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the Listing Agreement (i.e., presently the filing done under Regulation 31 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as of 30 June 2023).

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC. (***)

(***) Part- B shall be disclosed to the Stock Exchanges but shall not be disseminated.

For and on behalf of Berhyanda Limited

)
)
)
)
)
)



Authorised Signatory
Name: Christodoulos Patsalides
Designation: Director
Date: 29 September 2023
Place: Nicosia, Cyprus

**For and on behalf of Berhyanda Midco)
Limited**


)
)
)
)
)



Authorised Signatory
Name: Christakis Klerides
Designation: Director
Date: 29 September 2023
Place: Nicosia, Cyprus

For and on behalf of Jsmiral Midco Limited)

)
)
)
)
)
)
)



Authorised Signatory
Name: Christodoulos Patsalides
Designation: Director
Date: 29 September 2023
Place: Nicosia, Cyprus

Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011

Part A- Details of the Acquisition

Name of the Target Company (“TC”)	Suven Pharmaceuticals Limited		
Name(s) of the acquirer and Persons Acting in Concert (“PAC”) with the acquirer	Acquirer: Berhyanda Limited PAC 1: Berhyanda Midco Limited PAC 2: Jusmiral Midco Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	0	0%	0%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
c) Voting rights (“VR”) otherwise than by equity shares	0	0%	0%
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0	0%	0%
e) Total (a+b+c+d)	0	0%	0%

Details of acquisition			
a) Shares carrying voting rights acquired	12,75,37,043 #	50.10%#	50.10%#
b) VRs acquired otherwise than by equity shares	0	0%	0%
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	0	0%	0%
d) Shares in the nature of encumbrance (pledge/lien/ non-disposal undertaking/ others)	2,51,94,957 &	9.90%&	9.90%&
e) Total (a+b+c+d)	15,27,32,000#&	60.00% #&	60.00% #&
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	12,75,37,043 #	50.10%#	50.10%#
b) VRs otherwise than by equity shares	0	0%	0%
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	0	0%	0%
d) Shares in the nature of encumbrance (pledge/lien/ non- disposal undertaking/ others)	2,51,94,957 &	9.90%&	9.90%&
e) Total (a+b+c+d)	15,27,32,000#&	60.00% #&	60.00% #&
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/ encumbrance, etc.)	Acquisition by way of an “off-market” purchase pursuant to the SPA&.		
Salient features of the securities acquired including time till redemption, ratio, at which it can be converted into equity shares, etc.	Equity shares carrying voting rights&.		

Date of acquisition of shares/ date of receipt of intimation of allotment of shares /VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	29 September 2023
Equity share capital / total voting capital of the TC before the said acquisition	25,45,64,956 equity shares of the TC (as per the shareholding pattern as on 30 June 2023 as publicly disclosed by the TC)
Equity share capital/ total voting capital of the TC after the said acquisition	25,45,64,956 equity shares of the TC (as per the shareholding pattern as on 30 June 2023 as publicly disclosed by the TC)
Total diluted share/voting capital of the TC after the said acquisition	25,45,64,956 equity shares of the TC (as per the shareholding pattern as on 30 June 2023 as publicly disclosed by the TC)

[#] *The Acquirer has triggered a mandatory open offer in compliance with Regulations 3(1) and 4 and other applicable regulations of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“**Takeover Regulations**”), pursuant to the execution of the SPA (as defined in [&] below) to acquire more than 25% of the equity share capital of the Target Company and control over the Target Company. In this regard, the Acquirer has initiated the process for the open offer and has issued a public announcement on 26 December 2022, published the detailed public statement on 2 January 2023 and submitted a draft letter of offer with the Securities and Exchange Board of India on 9 January 2023, in accordance with the applicable provisions of the Takeover Regulations. The Acquirer has acquired 12,75,37,043 equity shares of the Target Company pursuant to the SPA in compliance with Regulation 22(2) of the Takeover Regulations.*

[&] *In terms of the share purchase agreement dated 26 December 2022, as amended (“**SPA**”) entered into between Berhyanda Limited (as Acquirer) (“**Acquirer**”), Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of Jasti Family Trust) (as Seller) (“**Seller**”) and Mr. Venkateswarlu Jasti (as Seller Representative) (“**Seller Representative**”), on and from consummation of the SPA (in terms of and subject to the SPA), and for a period of 18 months thereafter, the Seller and/or the Seller Representative shall not, without the prior written consent of the Acquirer, sell or otherwise encumber any equity shares of the TC held by them in favour of any person. As on the date of making this disclosure, the Seller and Seller Representative hold 2,51,92,957 equity shares (9.90% stake) and 2,000 equity shares (0.00% stake) in the TC respectively after the sale of 12,75,37,043 equity shares (50.10% stake) to the Acquirer pursuant to the SPA. Accordingly, such 2,51,92,957 equity shares (9.90% stake) and 2,000 equity shares (0.00% stake) represent shares taken by way of encumbrance by the Acquirer under Regulation 29(4) of the Takeover Regulations. The actual acquisition pursuant to the SPA by the Acquirer is limited to only 12,75,37,043 equity shares (50.10% stake) in the TC.*

For and on behalf of Berhyanda Limited

)
)
)
)
)
)



Authorised Signatory
Name: Christodoulos Patsalides
Designation: Director
Date: 29 September 2023
Place: Nicosia, Cyprus

**For and on behalf of Berhyanda Midco)
Limited**


)
)
)
)
)



Authorised Signatory
Name: Christakis Klerides
Designation: Director
Date: 29 September 2023
Place: Nicosia, Cyprus

For and on behalf of Jsmiral Midco Limited)

)
)
)
)
)
)
)



Authorised Signatory
Name: Christodoulos Patsalides
Designation: Director
Date: 29 September 2023
Place: Nicosia, Cyprus